253 related articles for article (PubMed ID: 30927552)
1. Promyelocytic leukemia protein (PML) controls breast cancer cell proliferation by modulating Forkhead transcription factors.
Sachini N; Arampatzi P; Klonizakis A; Nikolaou C; Makatounakis T; Lam EW; Kretsovali A; Papamatheakis J
Mol Oncol; 2019 Jun; 13(6):1369-1387. PubMed ID: 30927552
[TBL] [Abstract][Full Text] [Related]
2. Thiostrepton selectively targets breast cancer cells through inhibition of forkhead box M1 expression.
Kwok JM; Myatt SS; Marson CM; Coombes RC; Constantinidou D; Lam EW
Mol Cancer Ther; 2008 Jul; 7(7):2022-32. PubMed ID: 18645012
[TBL] [Abstract][Full Text] [Related]
3. miR-671-5p inhibits epithelial-to-mesenchymal transition by downregulating FOXM1 expression in breast cancer.
Tan X; Fu Y; Chen L; Lee W; Lai Y; Rezaei K; Tabbara S; Latham P; Teal CB; Man YG; Siegel RS; Brem RF; Fu SW
Oncotarget; 2016 Jan; 7(1):293-307. PubMed ID: 26588055
[TBL] [Abstract][Full Text] [Related]
4. Integrating bioinformatics and experimental models to investigate the mechanism of the chelidonine-induced mitotic catastrophe via the AKT/FOXO3/FOXM1 axis in breast cancer cells.
Li H; Tang X; Sun Z; Qu Z; Zou X
Biomol Biomed; 2024 May; 24(3):560-574. PubMed ID: 37976368
[TBL] [Abstract][Full Text] [Related]
5. The Forkhead box M1 protein regulates the transcription of the estrogen receptor alpha in breast cancer cells.
Madureira PA; Varshochi R; Constantinidou D; Francis RE; Coombes RC; Yao KM; Lam EW
J Biol Chem; 2006 Sep; 281(35):25167-76. PubMed ID: 16809346
[TBL] [Abstract][Full Text] [Related]
6. Forkhead box M1 (FoxM1) gene is a new STAT3 transcriptional factor target and is essential for proliferation, survival and DNA repair of K562 cell line.
Mencalha AL; Binato R; Ferreira GM; Du Rocher B; Abdelhay E
PLoS One; 2012; 7(10):e48160. PubMed ID: 23110199
[TBL] [Abstract][Full Text] [Related]
7. FOXM1 recruits nuclear Aurora kinase A to participate in a positive feedback loop essential for the self-renewal of breast cancer stem cells.
Yang N; Wang C; Wang Z; Zona S; Lin SX; Wang X; Yan M; Zheng FM; Li SS; Xu B; Bella L; Yong JS; Lam EW; Liu Q
Oncogene; 2017 Jun; 36(24):3428-3440. PubMed ID: 28114286
[TBL] [Abstract][Full Text] [Related]
8. Coordinated activation of c-Src and FOXM1 drives tumor cell proliferation and breast cancer progression.
Nandi I; Smith HW; Sanguin-Gendreau V; Ji L; Pacis A; Papavasiliou V; Zuo D; Nam S; Attalla SS; Kim SH; Lusson S; Kuasne H; Fortier AM; Savage P; Martinez Ramirez C; Park M; Katzenellenbogen JA; Katzenellenbogen BS; Muller WJ
J Clin Invest; 2023 Apr; 133(7):. PubMed ID: 36795481
[TBL] [Abstract][Full Text] [Related]
9. Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer.
McGovern UB; Francis RE; Peck B; Guest SK; Wang J; Myatt SS; Krol J; Kwok JM; Polychronis A; Coombes RC; Lam EW
Mol Cancer Ther; 2009 Mar; 8(3):582-91. PubMed ID: 19276163
[TBL] [Abstract][Full Text] [Related]
10. OTUB1 inhibits the ubiquitination and degradation of FOXM1 in breast cancer and epirubicin resistance.
Karunarathna U; Kongsema M; Zona S; Gong C; Cabrera E; Gomes AR; Man EP; Khongkow P; Tsang JW; Khoo US; Medema RH; Freire R; Lam EW
Oncogene; 2016 Mar; 35(11):1433-44. PubMed ID: 26148240
[TBL] [Abstract][Full Text] [Related]
11. The forkhead transcription factor FOXM1 promotes endocrine resistance and invasiveness in estrogen receptor-positive breast cancer by expansion of stem-like cancer cells.
Bergamaschi A; Madak-Erdogan Z; Kim YJ; Choi YL; Lu H; Katzenellenbogen BS
Breast Cancer Res; 2014 Sep; 16(5):436. PubMed ID: 25213081
[TBL] [Abstract][Full Text] [Related]
12. FOXM1 is a transcriptional target of ERalpha and has a critical role in breast cancer endocrine sensitivity and resistance.
Millour J; Constantinidou D; Stavropoulou AV; Wilson MS; Myatt SS; Kwok JM; Sivanandan K; Coombes RC; Medema RH; Hartman J; Lykkesfeldt AE; Lam EW
Oncogene; 2010 May; 29(20):2983-95. PubMed ID: 20208560
[TBL] [Abstract][Full Text] [Related]
13. FoxM1 down-regulation leads to inhibition of proliferation, migration and invasion of breast cancer cells through the modulation of extra-cellular matrix degrading factors.
Ahmad A; Wang Z; Kong D; Ali S; Li Y; Banerjee S; Ali R; Sarkar FH
Breast Cancer Res Treat; 2010 Jul; 122(2):337-46. PubMed ID: 19813088
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-802 suppresses breast cancer proliferation through downregulation of FoxM1.
Yuan F; Wang W
Mol Med Rep; 2015 Sep; 12(3):4647-4651. PubMed ID: 26080894
[TBL] [Abstract][Full Text] [Related]
15. FOXM1 cistrome predicts breast cancer metastatic outcome better than FOXM1 expression levels or tumor proliferation index.
Yau C; Meyer L; Benz S; Vaske C; Scott G; Egan B; Labhart P; Pourmand N; Benz CC
Breast Cancer Res Treat; 2015 Nov; 154(1):23-32. PubMed ID: 26456572
[TBL] [Abstract][Full Text] [Related]
16. FOXO transcription factors control E2F1 transcriptional specificity and apoptotic function.
Shats I; Gatza ML; Liu B; Angus SP; You L; Nevins JR
Cancer Res; 2013 Oct; 73(19):6056-67. PubMed ID: 23966291
[TBL] [Abstract][Full Text] [Related]
17. FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells.
Hamurcu Z; Ashour A; Kahraman N; Ozpolat B
Oncotarget; 2016 Mar; 7(13):16619-35. PubMed ID: 26918606
[TBL] [Abstract][Full Text] [Related]
18. ATM and p53 regulate FOXM1 expression via E2F in breast cancer epirubicin treatment and resistance.
Millour J; de Olano N; Horimoto Y; Monteiro LJ; Langer JK; Aligue R; Hajji N; Lam EW
Mol Cancer Ther; 2011 Jun; 10(6):1046-58. PubMed ID: 21518729
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of FOXM1 transcription factor suppresses cell proliferation and tumor growth of breast cancer.
Yang C; Chen H; Yu L; Shan L; Xie L; Hu J; Chen T; Tan Y
Cancer Gene Ther; 2013 Feb; 20(2):117-24. PubMed ID: 23306612
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive clinicopathological significance and putative transcriptional mechanisms of Forkhead box M1 factor in hepatocellular carcinoma.
Wu HY; Luo LF; Wei F; Jiang HM
World J Surg Oncol; 2023 Nov; 21(1):366. PubMed ID: 38001498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
